Profile data is unavailable for this security.
About the company
Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
- Revenue in CNY (TTM)1.09bn
- Net income in CNY101.68m
- Incorporated2002
- Employees1.68k
- LocationPulike Biological Engineering IncNo. 15, Zhenghe Road, Luolong DistrictLUOYANG 471000ChinaCHN
- Phone+86 37 963282386
- Fax+86 37 963282386
- Websitehttp://www.pulike.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals Inc | 530.47m | -8.70m | 4.34bn | 471.00 | -- | 4.77 | -- | 8.19 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.26bn | 247.04m | 4.35bn | 701.00 | 17.61 | 2.94 | -- | 3.47 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 713.75m | 233.79m | 4.40bn | 1.14k | 18.59 | 1.97 | -- | 6.16 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.37bn | 13.89m | 4.45bn | 1.85k | 202.11 | 1.67 | -- | 1.88 | 0.0502 | 0.0502 | 5.72 | 6.08 | 0.4094 | 1.74 | 6.76 | 1,284,337.00 | 0.2471 | 3.30 | 0.4806 | 5.97 | 21.35 | 32.35 | 0.6036 | 8.21 | 0.4855 | 1.21 | 0.4994 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Shanghai New World Co Ltd | 1.13bn | 45.48m | 4.55bn | 1.20k | 100.00 | 1.08 | -- | 4.01 | 0.0703 | 0.0703 | 1.75 | 6.53 | 0.201 | 3.94 | 10.25 | 942,735.10 | 0.7905 | 0.5242 | 1.05 | 0.7249 | 38.77 | 33.70 | 3.93 | 2.71 | 1.57 | -- | 0.1158 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Yabao Pharmaceutical Group Co Ltd | 2.83bn | 220.70m | 4.56bn | 4.14k | 20.71 | 1.54 | -- | 1.61 | 0.3057 | 0.3057 | 3.86 | 4.10 | 0.7389 | 3.51 | 6.66 | 683,686.80 | 5.11 | 2.82 | 6.38 | 3.97 | 52.85 | 59.20 | 6.92 | 4.19 | 2.04 | 129.51 | 0.0313 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Pulike Biological Engineering Inc | 1.09bn | 101.68m | 4.62bn | 1.68k | 45.08 | 1.73 | -- | 4.25 | 0.296 | 0.296 | 3.13 | 7.72 | 0.3373 | 2.48 | 2.65 | 646,748.50 | 3.16 | 7.64 | 3.73 | 8.96 | 60.45 | 62.57 | 9.36 | 17.85 | 2.51 | -- | 0.0086 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
Data as of Nov 22 2024. Currency figures normalised to Pulike Biological Engineering Inc's reporting currency: Chinese Yuan Renminbi CNY
7.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Origin Asset Management Co. Ltd.as of 17 Mar 2023 | 5.39m | 1.53% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 4.65m | 1.33% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 4.21m | 1.20% |
| Harvest Fund Management Co., Ltd.as of 17 Mar 2023 | 4.06m | 1.16% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 2.08m | 0.59% |
| JPMorgan Chase Bank, NA (Investment Management)as of 17 Mar 2023 | 1.68m | 0.48% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 1.37m | 0.39% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 1.17m | 0.33% |
| Soochow Asset Management Co., Ltd.as of 17 Mar 2023 | 1.12m | 0.32% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 1.09m | 0.31% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
